Stephen Ansell, MD, PhD Presentations

Great Debates in WM

Moderated by Carl Harrington- IWMF President
Rituxan Maintenance vs. No Maintenance
Morton Coleman MD – Weill Cornell Medical College vs. Stephen Ansell MD, PhD – Mayo Clinic, 2019 Ed Forum
Limited Treatment Duration vs. Continuous Pill
Edward Stadtmauer, MD – University of Pennsylvania vs. Jorge Castillo, MD – Dana Farber Cancer Institute, 2019 Ed Forum
The experts debate hot topics in long term treatment decisions for WM

Immunotherapy – Making the Immune System Target WM Cells

Stephen Ansell MD, PhD, Mayo Clinic, Rochester, 2019 Ed Forum
Explains how immunotherapy activates T-cells into killer T-cells and prevents them from being switched off, so that the T-cell has increased ability to target cancer cells. Over time, T-cells can become “exhausted” and switched off with loss of function.  Strategies to block these “switched off” signals with PD1 blockade and CTLA-4 blockade are presented. T-cells in WM are not activated, strategies are presented to activate the T-cell by “waking’ them up by giving them a “poke.” T-cells in WM also do not “lock on” to their targets. Chimeric antigen receptor (CAR) T-cell therapy may give the T-cell a new way to “dock” onto WM cells.

The Research Roadmap Roundup

Stephen Ansell MD, PhD – Mayo Clinic Rochester, 2018 Ed Forum
Provides the IWMF-LLS Strategic Research Roadmap and addresses the uniqueness of WM, its genomics, epigenomics, MYD88 L265P and CXCR4 mutations, and treatment options

Overview of the IWMF-LLS Strategic Research Roadmap – Our Track for the Future

Stephen Ansell, MD, PhD – Mayo Clinic Rochester, 2017 Ed Forum
Provides the IWMF-LLS Strategic Research Roadmap and addresses the uniqueness of WM, its genomics, epigenomics, MYD88 L265P and CXCR4 mutations, treatment options, and survival

An Exciting Time in Waldenstrom's!

Stephen M. Ansell MD, PhD – Mayo Clinic, Rochester, 2016 Ed Forum
Explains the IWMF-LLS Strategic Research Roadmap and its importance to the WM community

IWMF Research Roadmap Overview & Bone Marrow Tumor Microenvironment

Stephen Ansell, MD, PhD – Mayo Clinic, Rochester, 2016 Ed Forum
Covers what is unique about WM, as well as, genomics, epigenomics, MYD88 L265P and CXCR4 mutations, survival, and treatment options

Research and IWMF

Stephen M. Ansell MD, PhD – Mayo Clinic, Rochester, 2015 Ed Forum
Dr. Ansell talks about his interest in WM, the funding provided by the IWMF for his research, and the team effort he is involved in with WM patients and the IWMF.  He also discusses the current exciting times for WM in terms of research, with opportunities for improved treatments and the possibility of a cure in the near future.

How B-cells Work and Talk to Each Other

Stephen Ansell, MD, PhD – Mayo Clinic, Rochester, 2015 Ed Forum
Reviews how lymphocytes become plasma cells and then produce antibodies and activate the B-cell receptor pathway, the Toll-like receptor pathway, causes of increased production of IgM in WM, cytokines, chemokines, receptor/ligand interactions and cell communications

Pulling the Plug on Cancer Cell Communication

Stephen Ansell, MD, PhD – Mayo Clinic, Rochester, 2014 Ed Forum Covers why WM cells need to communicate and how they communicate, cytokine networks, B-cell receptor pathway, Toll-like receptor pathway, what goes wrong in WM, what causes the increased production of IgM in WM, B-lymphocyte stimulator (BLyS) increase in WM, and why we need to stop the communication

No video available